258 related articles for article (PubMed ID: 20201747)
21. Current opinions and controversies in chronic myeloid leukaemia.
Kishore B; Marin D
Curr Opin Oncol; 2011 Nov; 23(6):659-64. PubMed ID: 21918441
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate for the treatment of chronic myeloid leukemia.
Soverini S; Martinelli G; Iacobucci I; Baccarani M
Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
[TBL] [Abstract][Full Text] [Related]
23. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia.
le Coutre P; Schwarz M; Kim TD
Clin Cancer Res; 2010 Mar; 16(6):1771-80. PubMed ID: 20197479
[TBL] [Abstract][Full Text] [Related]
24. Chronic myeloid leukemia: Second-line drugs of choice.
Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
[TBL] [Abstract][Full Text] [Related]
25. Discontinuation of tyrosine kinase therapy in CML.
Mahon FX
Ann Hematol; 2015 Apr; 94 Suppl 2():S187-93. PubMed ID: 25814085
[TBL] [Abstract][Full Text] [Related]
26. Current status of agents active against the T315I chronic myeloid leukemia phenotype.
Burke AC; Swords RT; Kelly K; Giles FJ
Expert Opin Emerg Drugs; 2011 Mar; 16(1):85-103. PubMed ID: 21352071
[TBL] [Abstract][Full Text] [Related]
27. Management of early stage chronic myeloid leukemia: state-of-the-art approach and future perspectives.
Galaverna F; Ghiggi C; Guolo F; Beltrami G; Dellepiane C; Giannoni L; Carella A; Carella AM
Curr Cancer Drug Targets; 2013 Sep; 13(7):749-54. PubMed ID: 23952099
[TBL] [Abstract][Full Text] [Related]
28. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
29. Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.
Jalkanen SE; Vakkila J; Kreutzman A; Nieminen JK; Porkka K; Mustjoki S
Exp Hematol; 2011 Jan; 39(1):102-113.e1. PubMed ID: 20869423
[TBL] [Abstract][Full Text] [Related]
30. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
Deininger MW; Manley P
Leuk Res; 2012 Mar; 36(3):253-61. PubMed ID: 21996558
[TBL] [Abstract][Full Text] [Related]
31. Emerging therapies in chronic myeloid leukemia.
Gora-Tybor J
Curr Cancer Drug Targets; 2012 Jun; 12(5):458-70. PubMed ID: 22483154
[TBL] [Abstract][Full Text] [Related]
32. Molecular monitoring of response in patients with chronic myeloid leukemia.
Kolibaba KS
Manag Care; 2013 Jul; 22(7):40, 50-61. PubMed ID: 23936973
[TBL] [Abstract][Full Text] [Related]
33. Chronic myeloid leukemia: First-line drug of choice.
Jabbour E
Am J Hematol; 2016 Jan; 91(1):59-66. PubMed ID: 26769227
[TBL] [Abstract][Full Text] [Related]
34. Update on emerging treatments for chronic myeloid leukemia.
Fava C; Morotti A; Dogliotti I; Saglio G; Rege-Cambrin G
Expert Opin Emerg Drugs; 2015 Jun; 20(2):183-96. PubMed ID: 25826695
[TBL] [Abstract][Full Text] [Related]
35. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.
Perrone S; Massaro F; Alimena G; Breccia M
Expert Opin Pharmacother; 2016 Aug; 17(11):1517-26. PubMed ID: 27231757
[TBL] [Abstract][Full Text] [Related]
36. Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?
Breccia M; Efficace F; Alimena G
Leuk Res; 2012 Jul; 36(7):813-4. PubMed ID: 22483067
[No Abstract] [Full Text] [Related]
37. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.
Gugliotta G; Castagnetti F; Fogli M; Cavo M; Baccarani M; Rosti G
Expert Rev Hematol; 2013 Oct; 6(5):563-74. PubMed ID: 24083631
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.
Milojkovic D; Apperley J
Clin Cancer Res; 2009 Dec; 15(24):7519-7527. PubMed ID: 20008852
[TBL] [Abstract][Full Text] [Related]
39. Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?
Visani G; Isidori A
Expert Opin Pharmacother; 2014 Jan; 15(1):1-3. PubMed ID: 24152096
[TBL] [Abstract][Full Text] [Related]
40. Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest.
Heaney ML
Clin Adv Hematol Oncol; 2014 Aug; 12(8):502-8. PubMed ID: 25356574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
